DUBLIN–(BUSINESS WIRE)–Added Global Markets for Insulin Drug and Delivery Technologies report ResearchAndMarkets.com Offer.
The latest report provides a detailed insight into the Insulin Drugs and Delivery Technologies Market. This report analyzes the Insulin Drug and Delivery Technologies market trends with data from 2021, 2022 estimates, forecasts of compound annual growth rates up to 2027 (forecast period 2022-2027) and regional Insulin Drug and Delivery Technologies markets.
This report will highlight the current and future market potential of Insulin Drugs and Delivery Technologies along with a detailed analysis of the competitive landscape. Regulatory scenarios, drivers, restraints and opportunities are covered in the current report. The report also includes market forecasts for 2026 and market shares for key market players.
Insulin drug and delivery technologies are used to treat type 1 and type 2 diabetes. Convenient insulin delivery devices like smart pens help diabetic patients optimize blood glucose control and minimize the risk of related health problems. Advanced insulin delivery devices offer better patient compliance.
The traditional syringes and insulin pumps are being replaced by reusable and disposable insulin pens because the latter are portable, have higher dosing accuracy, have built-in memory, deliver larger doses and are easy to use. Traditional syringes and pumps have not seen a major breakthrough.
Major manufacturers of insulin delivery devices include Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG. The most important manufacturers of modern insulin and human insulin include Sanofi, Eli Lilly, Novo Nordisk, Boehringer Ingelheim International GmbH, Biocon and Viatris Inc.
The market growth is attributed to factors such as increasing incidence of diabetes and novel insulin drugs and delivery technologies. The global insulin drug and delivery technology market is segmented by device type, insulin type, and region.
In this report, the market has been segmented by device type, insulin type, and geographic region. Device types include syringes, insulin pens, insulin pumps, smart pens, and others. Types of insulin include long-acting, rapid-acting, premixed, intermediate-acting, and short-acting insulins.
Geographic regions covered include North America, Europe, Asia Pacific and the Rest of the World (RoW). Individual countries covered include the US, Germany, UK, Italy, France, Japan, China and India.
Descriptive company profiles of major manufacturers of modern insulin and insulin delivery devices, including Sanofi, Eli Lilly, Novo Nordisk, Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG
report includes
-
24 data tables and 31 additional tables
-
A current overview of the global markets for insulin drugs and delivery technologies
-
Analyzes of global market trends with historical market revenue (sales data) for 2020 and 2021, estimates for 2022 and projections of compound annual growth rates (CAGRs) up to 2027
-
Highlights of the current state of insulin drug and delivery industry structure, novel technological updates and issues related to insulin pens and insulin syringes, ongoing research activities, and regulatory and pricing scenarios
-
Estimation of actual market size and market forecast for Insulin Drug and Delivery Technologies along with related market share analysis by device type, insulin type, and geographic region
-
Updated information on the major mergers and acquisitions deals, partnerships, collaborations and other strategic alliances within the insulin drug and delivery technology industry
-
Analysis of market opportunities with a holistic review of Porter’s Five Forces analysis model, taking into account the micro and macro environmental factors prevailing in the market
-
Identification of key stakeholders and analysis of the competitive landscape based on recent developments and segment sales
Main topics covered:
Chapter 1 Introduction
1.1 Insulin overview
1.2 Diabetes Overview
1.2.1 Disease symptoms and risk factors
1.2.2 Epidemiology and economic burden
1.3 Study Aims and Objectives
1.4 Reasons for conducting this study
1.5 What’s new in this update?
1.6 Scope of the Report
1.7 Sources of Information
1.8 Methodology
1.9 Geographical Breakdown
1.10 Analyst Credentials
1.11 Custom Research
1.12 Related Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market Dynamics
3.1 Market Drivers
3.1.1 Increasing prevalence of diabetes
3.1.2 Smart Insulin Delivery Technologies
3.1.3 Technologies for Painless Insulin Delivery
3.2 Market Restrictions
3.2.1 Product Recalls
3.3 Market Opportunities
3.3.1 Inorganic Strategies Among Market Players
Chapter 4 Market Overview
4.1 Market Insights
4.1.1 Insulin
4.1.2 Diabetes
4.2 Current Market Trends
4.2.1 Recent Product Launches
4.2.2 Recent strategic alliances
4.3 Future Perspective
Chapter 5 Regulatory Landscape and Reimbursement Scenario
5.1 Regulatory Landscape
5.1.1 US Medical Device Regulations
5.1.2 US Drug Regulations
5.1.3 European Regulations for Medical Devices
5.1.4 European regulations for medicinal products
5.1.5 Asia Pacific Medical Device Regulations
5.2 Refund Scenario
5.2.1 Pricing and Refund Overview
5.2.2 Pricing and Reimbursement for Medical Devices
5.2.3 Drug Pricing and Reimbursement
5.3 Insurance
5.3.1 Insurance for diabetic emergencies
Chapter 6 Impact of Covid-19 on the market
6.1 Overview
6.2 Covid-19 Crisis
6.2.1 Impact on Insulin Drug and Delivery Technologies Market
6.2.2 Covid-19 measures
Chapter 7 Market Breakdown by Device Type
7.1 Insulin Delivery Technologies
7.1.1 Syringes
7.1.2 Insulin Pens
7.1.3 Insulin pumps
7.1.4 Smart Pens
7.1.5 Miscellaneous
Chapter 8 Market Breakdown by Insulin Type
8.1 Insulin
8.1.1 Structure of Insulin
8.1.2 Insulin Biosynthesis
8.1.3 Insulin Types
Chapter 9 Market Split by Regions
9.1 Overview
9.1.1 North America
9.1.2 Europe
9.1.3 Asia Pacific
9.1.4 Rest of the World
Chapter 10 Analysis of Market Opportunities
10.1 Porter’s Five Forces Analysis
10.1.1 Threat of New Entrants
10.1.2 Threat of Substitutes
10.1.3 Bargaining Power of Suppliers
10.1.4 Bargaining Power of Buyers
10.1.5 Level of Competition
Chapter 11 Competitive Landscape
Chapter 12 Company Profiles
12.1 Major Companies
-
B.Braun Melsungen AG
-
Becton, Dickinson and Co.
-
Biocon
-
Boehringer Ingelheim International GmbH
-
Eli Lilly and Co.
-
F. Hoffmann-La Roche AG
-
Medtronic Inc.
-
Novo Nordisk A/S
-
Sanofi
-
Viatris Inc.
-
Ypsomed Holding Ltd
-
other companies
-
Cequr simplicity
-
Debiotech Sat
-
Emperra GmbH E-Health Technologies
-
Islandt Corp.
-
Nanopass Technologies Ltd.
-
Nipro Medical Corp.
-
Owen Mumford Ltd.
-
Tandem Diabetes Care Inc.
For more information about this report, visit https://www.researchandmarkets.com/r/paod2q
